Cyclacel Pharmaceuticals Inc.
416 articles about Cyclacel Pharmaceuticals Inc.
-
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
3/13/2024
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2023 financial results on Tuesday, March 19, 2024.
-
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
3/7/2024
Cyclacel Pharmaceuticals, Inc. today announced that preclinical proof-of-concept data with the Company’s fadraciclib will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, California.
-
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
3/6/2024
Cyclacel Pharmaceuticals, Inc. announced that it received £2.3 million as a research & development tax credit from HMRC, the tax agency of the United Kingdom government.
-
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
2/20/2024
Cyclacel Pharmaceuticals, Inc. today announced that Spiro Rombotis, President and Chief Executive Officer, is scheduled to present at the 2024 BIO CEO & Investor Conference taking place in-person at the New York Marriott Marquis on February 26-27, 2024.
-
Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
1/30/2024
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that Brian Schwartz, M.D. will assume the role of interim Chief Medical Officer (“CMO”) of the Company effective immediately.
-
A lot of attention at JPM was focused on the cancer space. Executives from Olema Oncology and Cyclacel spoke with BioSpace about their plans for 2024 and why biotech’s kickoff conference is important to them.
-
Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
1/8/2024
Cyclacel Pharmaceuticals, Inc. announced today that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") on January 4, 2024, indicating that the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules.
-
Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024
1/2/2024
Cyclacel Pharmaceuticals, Inc. announced today that Spiro Rombotis, President & Chief Executive Officer, will present an overview of its business and provide updates on its clinical programs at Biotech Showcase, taking place January 8-10, 2024 in San Francisco, California.
-
Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules
12/22/2023
Cyclacel Pharmaceuticals, Inc. announced today that it has entered into a definitive agreement for the purchase and sale of 388,200 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.315 per share of common stock.
-
Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions
12/18/2023
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today interim results from its Phase 1, dose escalation 065-101 study of fadraciclib (“fadra”) in patients with advanced solid tumors and lymphoma.
-
Cyclacel Pharmaceuticals Announces Reverse Stock Split - December 12, 2023
12/12/2023
Cyclacel Pharmaceuticals, Inc. announced that it will implement a 1-for-15 Reverse Stock Split of its common stock, effective at 5:00 p.m. Eastern Time on Friday, December 15, 2023.
-
Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC
11/30/2023
Cyclacel Pharmaceuticals, Inc. today announced that it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained compliance with Nasdaq Listing Rule 5250(c)(1).
-
Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q
11/28/2023
Cyclacel Pharmaceuticals, Inc. announced that it received a notice of non-compliance from Nasdaq Stock Market LLC on November 21, 2023 stating that, as a result of not having timely filed its quarterly report on Form 10-Q for the quarter ended September 30, 2023, the Company is not in compliance with Nasdaq Listing Rule 5250, which requires timely filing of periodic financial reports with the U.S. Securities and Exchange Commission.
-
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
11/13/2023
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today third quarter financial results and provided a business update.
-
Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results
11/7/2023
Cyclacel Pharmaceuticals, Inc. will announce third quarter 2023 financial results on Monday, November 13, 2023.
-
Cyclacel Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
8/9/2023
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical leader in cell cycle checkpoint control developing innovative medicines based on cancer cell biology, announced second quarter financial results and provided a business update.
-
Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results
8/3/2023
Cyclacel Pharmaceuticals, Inc. will announce second quarter 2023 financial results on Wednesday August 9, 2023. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day.
-
Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
5/11/2023
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical leader in cell cycle checkpoint control developing innovative medicines based on cancer cell biology, announced today first quarter financial results and provided a business update.
-
Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results
5/4/2023
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2023 financial results on Thursday, May 11, 2023.
-
Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit
5/3/2023
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that it received a payment of £3.9 million as a research & development tax credit from HMRC, the tax agency of the United Kingdom government.